Share Fund
The primary objective of the scheme is to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector. However, there can be no assurance or guarantee that the investment objective of the scheme would be achieved.
Scheme Class | Equity |
Scheme Category | Sector - Healthcare |
Expense Ratio | 1.3% |
Min subscription | ₹ 5,000 |
Scheme Type | Open-ended |
Scheme AUM (in Crs.) | ₹ 1,089 |
AMC AUM (in Crs.) | ₹ 1,59,694 |
Min Addition Subscription | ₹ 1,000 |
Benchmark Type | S&P BSE Healthcare PR |
Exit Load | Exit load of 1.0%, if redeemed between (0-30) days. No Exit load, if redeemed after 30 days. |
Fund | Min SIP Inv. | Min Inv. | Returns 3Y |
---|---|---|---|
SBI Healthcare Opportunities Fund - Direct Plan | 0 | 0 | 26.06% |
SBI Healthcare Opportunities Fund - Direct Plan | 0 | 0 | 26.06% |
Nippon India Pharma Fund - Direct Plan | 1000 | 1000 | 21.05% |
UTI Healthcare Fund - Direct Plan | 0 | 0 | 22.7% |
Nippon India Pharma Fund - Direct Plan | 1000 | 1000 | 21.05% |
UTI Healthcare Fund - Direct Plan | 0 | 0 | 22.7% |
Company | Holding Type | Asset(%) |
---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | 12 |
Cipla Ltd | Equity | 7 |
Ajanta Pharma Ltd | Equity | 6 |
Dr Reddy's Laboratories Ltd | Equity | 5 |
Apollo Hospitals Enterprise Ltd | Equity | 4 |
Procter & Gamble Health Ltd | Equity | 4 |
Glenmark Pharmaceuticals Ltd | Equity | 3 |
Aurobindo Pharma Ltd | Equity | 3 |
Krishna Institute of Medical Sciences Ltd | Equity | 3 |
Gland Pharma Ltd | Equity | 3 |
Asset | Percent |
---|---|
Equity | 99 |
Cash | 1 |
0 | |
Cash - Repurchase Agreement | 0 |
Sector | Percent |
---|---|
Healthcare | 96 |
Basic Materials | 1 |
Cash | 1 |
Financial Services | 1 |
0 |
Fund Manager
Kamal Gada
2+ years of experience
About
pms_care@uti.co.in
Phone
1800 26 61230
Address
PMS Division, UTI - Tower, Gn Block, Bandra Kurla Complex, Mumbai- 400051, Mumbai - 400051